» Articles » PMID: 26016486

Staphylococcus Aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

Overview
Specialty Microbiology
Date 2015 May 29
PMID 26016486
Citations 1841
Authors
Affiliations
Soon will be listed here.
Abstract

Staphylococcus aureus is a major human pathogen that causes a wide range of clinical infections. It is a leading cause of bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related infections. This review comprehensively covers the epidemiology, pathophysiology, clinical manifestations, and management of each of these clinical entities. The past 2 decades have witnessed two clear shifts in the epidemiology of S. aureus infections: first, a growing number of health care-associated infections, particularly seen in infective endocarditis and prosthetic device infections, and second, an epidemic of community-associated skin and soft tissue infections driven by strains with certain virulence factors and resistance to β-lactam antibiotics. In reviewing the literature to support management strategies for these clinical manifestations, we also highlight the paucity of high-quality evidence for many key clinical questions.

Citing Articles

Staphylococcus borealis causing subclinical mastitis in dromedary camels.

Ranjan R, Kuniyal A, Ranjan A, Singh M, Jyotsana B, Sawal R Trop Anim Health Prod. 2025; 57(2):117.

PMID: 40085299 DOI: 10.1007/s11250-025-04372-0.


Mechanisms of Overexpression and Membrane Potential Reduction Leading to Ciprofloxacin Heteroresistance in a Isolate.

Li M, Jian Q, Ye X, Jing M, Wu J, Wu Z Int J Mol Sci. 2025; 26(5).

PMID: 40076991 PMC: 11901101. DOI: 10.3390/ijms26052372.


Nitroreductase-activatable photosensitizers for selective antimicrobial photodynamic therapy.

Tung M, Ma T, Lopez-Miranda I, Milstein J, Beharry A RSC Med Chem. 2025; .

PMID: 40060997 PMC: 11883423. DOI: 10.1039/d4md00890a.


Antibacterial and anti-biofilm activities of Derazantinib (ARQ-087) against Staphylococcus aureus.

Wang W, Zhong Q, Huang X Arch Microbiol. 2025; 207(4):78.

PMID: 40047947 DOI: 10.1007/s00203-025-04288-1.


Early fibrin biofilm development in cardiovascular infections.

Oukrich S, Hong J, Leon-Grooters M, van Cappellen W, Slotman J, Koenderink G Biofilm. 2025; 9:100261.

PMID: 40034339 PMC: 11872660. DOI: 10.1016/j.bioflm.2025.100261.


References
1.
Kaandorp C, Dinant H, van de Laar M, Moens H, Prins A, Dijkmans B . Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Ann Rheum Dis. 1997; 56(8):470-5. PMC: 1752430. DOI: 10.1136/ard.56.8.470. View

2.
Osterholm M, Forfang J . Toxic-shock syndrome in Minnesota: results of an active-passive surveillance system. J Infect Dis. 1982; 145(4):458-64. DOI: 10.1093/infdis/145.4.458. View

3.
Tarakji K, Chan E, Cantillon D, Doonan A, Hu T, Schmitt S . Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm. 2010; 7(8):1043-7. DOI: 10.1016/j.hrthm.2010.05.016. View

4.
Schweizer M, Furuno J, Harris A, Johnson J, Shardell M, McGregor J . Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011; 11:279. PMC: 3206863. DOI: 10.1186/1471-2334-11-279. View

5.
Uckay I, Tovmirzaeva L, Garbino J, Rohner P, Tahintzi P, Suva D . Short parenteral antibiotic treatment for adult septic arthritis after successful drainage. Int J Infect Dis. 2012; 17(3):e199-205. DOI: 10.1016/j.ijid.2011.12.019. View